Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491664 | 0.79 | TXNRD1 (0.50) | TXNRD1TXNRD3TXNRD2SMN1; SMN2HPGD | |
| SCHEMBL29661290 | 0.78 | TXNRD1 (0.53) | TXNRD1TXNRD3TXNRD2SMN1; SMN2TSHR | |
| SCHEMBL24327364 | 0.78 | TXNRD1 (0.53) | TXNRD1TXNRD3TXNRD2SMN1; SMN2TSHR | |
| SCHEMBL5723712 | 0.78 | TXNRD1 (0.53) | TXNRD1TXNRD3TXNRD2TSHRCYP3A4 | |
| SCHEMBL28958003 | 0.78 | TXNRD1 (0.53) | TXNRD1TXNRD3TXNRD2SMN1; SMN2TP53 | |
| SCHEMBL3540216 | 0.77 | TXNRD1 (0.49) | TXNRD1TXNRD3TXNRD2SMN1; SMN2TSHR | |
| SCHEMBL2265157 | 0.77 | AOC3 (0.44) | SMN1; SMN2HPGDCYP3A4HIF1AALDH1A1 | |
| SCHEMBL11032479 | 0.75 | TXNRD1 (0.68) | TXNRD1TXNRD3TXNRD2GPR35ALDH1A1 | |
| SCHEMBL4495775 | 0.75 | TXNRD1 (0.54) | TXNRD1TXNRD3TXNRD2SMN1; SMN2CYP3A4 | |
| SCHEMBL30077309 | 0.74 | GPR35 (0.43) | TXNRD1TXNRD3TXNRD2SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | INVASC THERAPEUTICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2539317-A2 | DIHYDROLIPOIC ACID DERIVATIVES COMPRISING NITRIC OXIDE AND THERAPEUTIC USES THEREOF | Invasc Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8198317-B2 | Methylenedioxy phenolic compounds and their use to treat disease | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | CARMEL BIOSCIENCES, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2324005-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | The Ohio State University Research Foundation (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010096677-A2 | DIHYDROLIPOIC ACID DERIVATIVES COMPRISING NITRIC OXIDE AND THERAPEUTIC USES THEREOF | INVASC THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010017323-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035849-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035849-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | REN, PCSK9, ALOX12 | TXNRD1 1455/4885TXNRD3 663/4885TXNRD2 104/4885 |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | DLD, LDLR, ALOX15 | TXNRD1 394/4885TXNRD3 355/4885TXNRD2 127/4885 |
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | REN, PCSK9, COMT | TXNRD1 1560/4885TXNRD3 710/4885TXNRD2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.